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Exosomes as nanocarriers 
for systemic delivery of the 
Helicobacter pylori virulence factor 
CagA
Asako Shimoda1,2, Koji Ueda3, Shin Nishiumi4, Naoko Murata-Kamiya5, Sada-atsu Mukai1,2, 
Shin-ichi Sawada1,2, Takeshi Azuma4, Masanori Hatakeyama5 & Kazunari Akiyoshi1,2
CagA, encoded by cytotoxin-associated gene A (cagA), is a major virulence factor of Helicobacter pylori, 
a gastric pathogen involved in the development of upper gastrointestinal diseases. Infection with cagA-
positive H. pylori may also be associated with diseases outside the stomach, although the mechanisms 
through which H. pylori infection promotes extragastric diseases remain unknown. Here, we report 
that CagA is present in serum-derived extracellular vesicles, known as exosomes, in patients infected 
with cagA-positive H. pylori (n = 4). We also found that gastric epithelial cells inducibly expressing CagA 
secrete exosomes containing CagA. Addition of purified CagA-containing exosomes to gastric epithelial 
cells induced an elongated cell shape, indicating that the exosomes deliver functional CagA into cells. 
These findings indicated that exosomes secreted from CagA-expressing gastric epithelial cells may 
enter into circulation, delivering CagA to distant organs and tissues. Thus, CagA-containing exosomes 
may be involved in the development of extragastric disorders associated with cagA-positive H. pylori 
infection.
Helicobacter pylori is a gram-negative bacterium that colonises the human stomach. Nearly half of the world 
population has been estimated to be carriers of H. pylori, and infection with H. pylori is associated with the 
pathogenesis of gastric disorders, such as atrophic gastritis, peptic ulcers, and gastric cancer1–3. Among reported 
H. pylori virulence factors, much attention has been focused on CagA, a protein encoded by cytotoxin associated 
gene A (cagA), because of its strong association with severe gastric lesions, particularly gastric cancer4,5. CagA is a 
bacterial effector protein that is injected into gastric epithelial cells via the type IV secretion system (T4SS). Inside 
host epithelial cells, CagA undergoes tyrosine phosphorylation by Src family kinases (SFKs) and acts as a pathogenic 
scaffold that promiscuously perturbs signalling pathways regulating cell growth, motility, and polarity, thereby 
promoting neoplastic transformation of cells6–12. Indeed, transgenic mice systemically expressing the bacterial 
cagA gene exhibit gastric epithelial hyperplasia, gastrointestinal carcinomas, and B cell lymphomas, indicating 
that CagA acts as an oncoprotein in mammals13.
Recent studies have also suggested that H. pylori infection is involved in the development of diseases outside 
the stomach, including cardiovascular diseases, haematologic diseases, diabetes mellitus, idiopathic parkinsonism, 
and others14–18. Additionally, H. pylori or other Helicobacter species have been detected in atherosclerotic plaques 
from patients; several mechanisms have been proposed, including direct effects of the bacterium on the vascular 
wall to induce endothelial dysfunction, indirect effects including the promotion of systemic inflammation and 
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production of inflammatory mediators, and induction of molecular mimicry by the production of cross-reactive 
antibodies19,20. However, the specific mechanisms mediating the extragastric effects of H. pylori remain unclear. 
In particular, infection with H. pylori cagA-positive strains has been shown to be associated with coronary heart 
diseases21–23 and ischemic stroke24–26. Preeclampsia, a pregnancy-associated disorder characterised by hypertension 
and proteinuria, is another vascular disease related to cagA-positive H. pylori infection27,28. These studies indicate 
that CagA may also contribute to the development of extragastric diseases29.
Many types of cells are known to release extracellular vesicles (EVs) with unique biophysical and biochemical 
properties30,31. These vesicles are classified based on their biogenesis; vesicles formed by exocytosis of multivesic-
ular bodies are referred as exosomes (with diameters ranging from 30 to 200 nm), while vesicles budded directly 
from the plasma membrane are referred to as microvesicles (with diameters ranging from 100 to 1000 nm)32. EVs 
are found in various biological fluids, including blood, urine, saliva, and breast milk, and they have been shown 
to play an important role in cell-to-cell communication through transport of informative constituents, including 
proteins, lipids, and microRNAs (miRNAs)33,34. Many exosomal miRNAs have been identified, and their sorting 
is modulated in a cell-dependent manner. For example, exosomes containing miRNAs released from cancer cells 
are involved in tumorigenesis and metastasis and have been shown to act as cancer biomarkers35. Recent studies 
have also demonstrated the role of EVs in the transfer of proteins during infection, including prion protein (PrP) 
in neurodegenerative disease36, human immunodeficiency virus (HIV)-related proteins37, and human T-cell leu-
kaemia virus type-1 (HTLV-1) proteins38. However, functions of exosomes as nanocarriers of pathogen-associated 
molecules during the development of various diseases are not well understood.
In this study, we aimed to elucidate the mechanisms through which CagA induces extragastric lesions in 
individuals infected with cagA-positive H. pylori. We found that exosomes containing CagA were released from 
H. pylori CagA-expressing cells and were detectable in the blood circulation, suggesting that CagA-containing 
exosomes could mediate the development of multiple extragastric diseases.
Results
Detection of CagA in serum exosomes isolated from cagA-expressing H. pylori-positive 
patients with gastric cancer. Serum-derived exosomes were collected from cagA-positive H. pylori-in-
fected patients with gastric cancer (the sample was prepared by mixing sera from four patients) and from H. 
pylori-uninfected healthy donor (n = 1) by ultracentrifugation. Transmission electron microscopy (TEM) and 
nanoparticle tracking analysis (NTA) demonstrated the presence of round-shaped vesicles measuring 20–150 nm 
(Supplementary Figure S1). To investigate whether CagA was present in the exosomes from cagA-positive H. 
pylori-infected patients, exosomes were analysed by liquid chromatography-tandem mass spectrometry (LC-MS/
MS). Detection of known exosomal surface antigens, including CD9, CD63 (see Supplementary Table S1 and 
Supplementary Figure S2), CD81, and CD8230, indicated that exosomes were effectively enriched by the ultra-
centrifugal procedure (Supplementary Tables S2 and S3). From SEQUEST database search analysis, four CagA-
derived tryptic peptides were significantly identified with a false discovery rate (FDR) of less than 1% (Table 1 and 
Supplementary Figure S3); the amino acid sequences of these peptides were identical to H. pylori Japanese strain 
F32. The extracted ion chromatograms of four peptides (CagA 166–178, 601–610, 995–1006, and 1047–1057) 
acquired from H. pylori-infected or -uninfected individuals are shown in Fig. 1A,B, respectively. All four peptides 
were specifically detected in serum exosomes from H. pylori-infected patients with gastric cancer but not from 
uninfected individuals. Other virulence factors from H. pylori, including Gamma-glutamyltransferase (GGT) 
and VacA, were not detected in serum-derived exosomes. These data revealed that circulating serum exosomes 
in H. pylori-infected patients contained CagA, suggesting that CagA could be delivered to nongastrointestinal 
compartments via circulating exosomes.
Isolation and characterisation of exosomes from CagA-expressing gastric epithelial cells. To 
investigate the mechanism underlying the generation of CagA-positive exosomes and to examine the biologi-
cal functions of CagA-containing exosomes, we used WT-A10 gastric epithelial cells, which can be induced to 
express wild-type CagA via a tetracycline-regulated Tet-off system, which mimics CagA injection by H. pylori 
into the host cells8, and the level of the CagA protein inducibly expressed in WT-A10 cells is roughly compa-
rable to that expressed in AGS cells co-cultured with H. pylori11. After culturing WT-A10 cells in the absence 
or presence of doxycycline (Dox), a tetracycline analogue, exosomes were collected from culture supernatants 
using differential centrifugation and analysed by sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) and western blotting. CagA was specifically detected in cell lysates and exosomes prepared from 
CagA-expressing cells (Dox–, CagA +; Fig. 2A). We also confirmed the presence of the exosome markers CD9 
and heat-shock protein 70 (HSP70)39. These marker proteins were detected in both CagA-expressing exosomes 
Peak 






number Sequence XCorr4 SpScore5
a 584.2863 2 15.1 E6NP29 cag pathogenicity island protein 601–610 NTGNYDEVKK 2.11 240
b 646.3060 2 19.3 E6NP29 cag pathogenicity island protein 1047–1057 LDNYATNSHTR 2.12 627
c 406.5489 3 47.8 E6NP29 cag pathogenicity island protein 995–1006 IGDLSQAVSEAK 1.42 243
d 708.9030 2 92.1 E6NP29 cag pathogenicity island protein 166–178 QSFAGIIIGNQIR 3.88 1041
Table 1.  CagA protein identified in H. pylori-infected human serum exosomes by LC-MS/MS. 1IDs 
correspond to peaks in Figure 1. 2Mass-to-charge ratio. 3Retention time of nano-HPLC. 4Cross correlation score 
by SEQUEST search. 5Identity threshold score by SEQUEST search.
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and exosomes not containing CagA. Next, the morphologies and sizes of exosomes were evaluated using TEM 
and NTA (Fig. 2B,C). TEM images showed round-shaped vesicles with lipid bilayers. The average diameters of 
exosomes were around 120 nm, as shown by NTA analysis.
To assess the localisation of CagA in the exosomes, trypsin digestion assays were performed with or without 
detergent (TritonX-100), followed by western blot analysis40,41. When the exosomes were treated with trypsin in the 
absence of TritonX-100, CagA was protected from trypsin-dependent enzymatic degradation. In contrast, in the 
presence of both trypsin and TritonX-100, CagA was completely degraded (Fig. 2D and Supplementary Figure S4). 
These results indicated that CagA was located inside the exosomes.
Induction of CagA-dependent morphological changes by CagA-containing exosomes. In 
host gastric epithelial cells, CagA undergoes tyrosine phosphorylation by SFKs. Since tyrosine phosphorylation 
activates the ability of CagA to induce an elongated cell-shape, known as the hummingbird phenotype11, we 
hypothesised that CagA protein in exosomes released from CagA-expressing gastric epithelial cells may also 
contain the tyrosine-phosphorylated form of CagA. To test this idea, cell lysates and exosomes prepared from 
CagA-expressing cells or cells not expressing CagA were separated by SDS-PAGE and subjected to western blot 
analysis using an anti-phosphotyrosine antibody (anti-PY). The results revealed that tyrosine-phosphorylated 
CagA was present in both cell lysates and exosomes prepared from CagA-expressing cells (Fig. 3A and 
Supplementary Figure S5). Accordingly, exosomes released from CagA-expressing gastric epithelial cells con-
tained tyrosine-phosphorylated CagA.
Tyrosine-phosphorylated CagA specifically induces a highly elongated cell-shape known as the hum-
mingbird phenotype in gastric epithelial cells11. Thus, we next investigated whether treatment of gastric epi-
thelial cells with CagA-containing exosomes could induce morphological changes in the cells upon delivery of 
tyrosine-phosphorylated CagA. For this experiment, CagA-expressing exosomes and exosomes not containing 
CagA, prepared from induced WT-A10 cells expressing CagA and uninduced WT-A10 cells or AGS cells not 
expressing CagA, were added to cultures of AGS cells (5 μ g protein/3.5 × 104 cells). At 24 h after exosome treatment, 
the morphology of AGS cells was evaluated by microscopy. When AGS cells were treated with CagA-negative 
exosomes, no overt morphological changes were observed (Fig. 3B). In contrast, treatment of AGS cells with 
CagA-positive exosomes elicited the hummingbird phenotype in approximately 20% of cells (Fig. 3C). These 
results indicated the exosomes delivered tyrosine-phosphorylated CagA into AGS cells and subsequently induced 
morphological changes in the cells. Practically, it is impossible to determine the ratio of the phosphorylation of 
CagA proteins in exosomes from the intensity of the bands by Western blot analysis because the anti-PY anti-
body and the anti-CagA antibody have different affinities to the CagA proteins. Therefore, CagA proteins within 
exosomes isolated from WT-A10 cells may exist as a mixture of phosphorylated-CagA and non-phosphorylated 
CagA. Even so, it may be possible for non-phosphorylated CagA to be phosphorylated in recipient cells and to 
induce the hummingbird phenotype. Consistent with this, internalisation of PKH67-labelled exosome in AGS 
cells was observed by confocal laser-scanning microscopy. Thus, exosomes were efficiently internalised into AGS 
cells regardless of the expression of CagA protein (Fig. 3D).
Discussion
In this study, we investigated the mechanisms through which CagA can induce extragastric lesions upon H. pylori 
infection. We found that exosomes containing CagA were detectable in the blood of individuals infected with 
cagA-positive H. pylori. We also found that the CagA-containing exosomes were released from gastric epithelial cells 
A B
Figure 1. Mass spectrometric identification of exosomal CagA protein in H. pylori-infected human serum. 
Exosomes were isolated from H. pylori-infected. (A) or uninfected (B) human serum and analysed by LC-MS/
MS. Extracted ion chromatograms (XICs) of CagA-derived peptides are shown. The targeted mass-to-charge 
ratios (m/z values) were 584.2863 (a), 646.3060 (b), 406.5489 (c), or 708.9030 (d), respectively. Peak IDs in a–d 
correspond to those in Table 1.
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Figure 2. Characterisation of WT-A10 cell-derived exosomes. (A) WT-A10 cell lysates and exosomes were 
analysed by western blotting using antibodies against HA, CagA, and exosomal markers (CD9 and HSP70). 
Inducible expression of HA-tagged CagA in WT-A10 cells was regulated by treatment with or without 
doxycycline (Dox). (B) The size distribution of CagA-positive exosomes (left) and CagA-negative exosomes 
(right) obtained by NTA. The data represent the mean ± SD (n = 5). (C) Morphologies of CagA-positive 
exosomes (left) and CagA-negative exosomes (right) were observed by TEM. Scale bar = 100 nm. (D) CagA 
protein was found inside the exosome. CagA-positive exosomes were incubated with trypsin in the absence or 
presence of 0.2% TritonX-100 at 37 °C for 5 min. The samples were separated by SDS-PAGE and analysed by 
western blotting using antibodies against HA.
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Figure 3. CagA-positive exosomes induced morphological changes in AGS cells. (A) Detection of tyrosine-
phosphorylated CagA in whole cell lysates and exosomes by western blotting using an anti-phosphotyrosine 
antibody. The same membrane blot was stripped and reprobed with anti-CagA antibody. (B) AGS-derived 
exosomes, WT-A10-derived CagA-negative exosomes, and WT-A10-derived CagA-positive exosomes were 
added to AGS cells (5 μ g protein/ 3.5 × 104 cells), and cell morphologies were observed by light microscopy. 
Arrows indicate the hummingbird phenotype. Scale bar = 50 μ m. (C) The percentages of hummingbird cells 
induced by CagA-negative and CagA-positive exosomes were calculated. Error bars indicate the mean ± SD 
(n = 3); *p < 0.001, Student’s t-test. (D) Uptake of CagA-negative and CagA-positive exosomes. These exosomes 
were labelled with PKH67 dye as described in the Methods. PKH67-labeled exosomes were added to AGS cells 
(5 μ g protein/3.5 × 104 cells). Cells were visualised using a confocal laser scanning microscope.
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expressing CagA. Collectively, these findings suggested that H. pylori CagA-containing exosomes could facilitate 
the development of multiple extragastric diseases.
Infection with H. pylori, particularly virulent cagA-positive strains, is causally associated with the development 
of severe gastric diseases, such as peptic ulcerations and gastric cancer. H. pylori cagA-positive strains specif-
ically colonise the human stomach, where they deliver the cagA-encoded CagA protein into gastric epithelial 
cells via type IV secretion. We assumed that H. pylori-delivered CagA is released from the host gastric epithelial 
cells as a component of exosomes, which enter into systemic circulation and thereby deliver CagA to remote 
organs and/or tissues through the blood. Tyrosine-phosphorylated CagA is the active form of CagA and has 
been shown to impair physiological cellular functions by acting as a pathogenic scaffold that perturbs multiple 
intracellular signalling pathways4,11. A previous study demonstrated that the biological half-life of unphospho-
rylated or tyrosine-phosphorylated CagA is relatively short (approximately 200 min) in gastric epithelial cells42. 
On the other hand, our finding suggested that CagA secreted from gastric epithelial cells existed stably in the 
tyrosine-phosphorylated form within exosomes.
Recent epidemiological studies have also suggested correlations between H. pylori infection and several non-
gastrointestinal diseases, most notably cardiovascular diseases43. Anti-CagA antibodies are suspected to cross-react 
with self-antigens exposed on the surface and/or present in the cytoplasm of endothelial cells, thereby triggering 
inflammation and deteriorating vascular lesions underlying coronary heart diseases, cerebral stroke, and preec-
lampsia44,45. Chronic gastritis caused by cagA-positive H. pylori also induces a mild but systemic inflammation 
status via increased levels of circulating pro-inflammatory cytokines46, which further accelerates the development 
of cardiovascular diseases. Our study suggested that CagA may contribute to the development of vascular lesions 
via delivery by exosomes, providing a novel mechanism to explain the extragastric effects of H. pylori infection.
GGT, another virulence factor in H. pylori, induces apoptosis in gastric epithelial cells47. GGT in H. suis, a 
relative of H. pylori that may also cause gastric lesions, is secreted in the form of exosome-like vesicles (outer 
membrane vesicles [OMVs]), which can translocate across the epithelial layers and deliver the enzyme to mucosal 
lymphocytes, thereby inhibiting their proliferation48. Thus, OMVs can be regarded as pathogenic carriers from the 
bacteria to the host cells. Vacuolating cytotoxin A (VacA), yet another important virulence factor in H. pylori, is 
released in both free form and membrane-associated form and enters epithelial cells via endocytosis49. Although 
H. pylori can release OMVs, which contain bacterial components including CagA, in the stomach lumen where 
the stomach pathogen colonizes, the presence of OMVs in the host (human) blood has not been reported so far. 
Furthermore, the biogenesis and components of OMVs are different from these of human cells-derived exosomes50. 
We found for the first time that CagA-containing exosomes are detectable in the blood of individuals infected 
with cagA-positive H. pylori in the stomach and at the same time demonstrated that exosomes released from from 
gastric epithelial cells inducibly expressing CagA were effectively internalised by epithelial cells and induced an 
elongated cell shape, indicating that the exosomes delivered functional CagA into cells. The functional role of 
exosomes as a transporter of various substances has been recently described51. The exosomes are internalised into 
various cells by endocytosis or membrane fusion52. CagA-containing exosomes circulating within blood vessels 
may adhere to the endothelial monolayer and deliver the CagA protein into endothelial cells. Since CagA stimulates 
the nuclear factor kappaB (NF-κB) signalling pathway in a cell-autonomous manner53,54 hyperactivated NF-κ B 
in CagA-delivered endothelial cells may promote atherosclerosis, a chronic inflammatory condition leading to 
endothelial cell dysfunction and eventually plaque formation and evolution, thereby predisposing individuals to 
coronary heart diseases, such as angina pectoris and myocardial infarction55. CagA-containing exosomes may 
also directly fuse with atherosclerotic plaques. This in turn enables exposure of CagA on the plaque surface and 
allows recognition by anti-CagA antibodies, thereby triggering immune reactions in the atherosclerotic lesion. In 
the case of idiopathic thrombocytopenic purpura (ITP), anti-CagA antibodies have been reported to cross-react 
with a 55-kDa platelet protein, suggesting molecular mimicry mechanisms underlying the development of ITP56. 
However, because the molecular nature of the protein recognised by anti-CagA antibodies has not been elucidated, 
it is possible that the 55-kDa protein is a CagA fragment delivered into platelets via exosomes. Because CagA is a 
bacterial oncoprotein57, exosome-mediated CagA delivery may also be involved in the development of neoplasias 
outside the stomach. In fact, epidemiological studies suggested that infection with H. pylori cagA-positive strains 
increases the risk of colorectal cancer58 and pancreatic cancer59. Thus, further studies are required to determine 
the potential role of CagA-containing exosomes in the enhancement of oncogenesis other than gastric cancer.
In conclusion, our study revealed an unprecedented mechanism for the delivery of microbial virulence factors 
to sites distant from the primary infection site, which may provoke more systemic clinical effects or symptoms 
that are seemingly unrelated to the primary infection. Further studies are needed to determine whether such a 
mechanism may also be involved in chronic virus infection or colonisation of commensal bacteria.
Methods
Serum samples. This study was approved by the ethics committee of Kobe University Graduate School of 
Medicine, and human samples were used in accordance with the guidelines of Kobe University Hospital. Blood 
samples were collected from four patients with gastric cancer, who were diagnosed at Kobe University Hospital. 
Written informed consent was obtained from all participants. Serum samples were prepared using a standard 
venous blood sampling protocol. The collected blood was centrifuged at 3,000 × g for 10 min at 4 °C, and the 
serum was then transferred to a clean tube, followed by storage at − 80 °C until use. Serum anti-H. pylori IgG 
levels of greater than 10 U/mL were judged as positive for H. pylori infection; the four patients with gastric cancer 
in this study were positive for H. pylori infection. To isolate a sufficient amount of exosomes from serum, serum 
samples obtained from the four patients with gastric cancer were mixed, and exosomes were then isolated from 
the combined serum sample. Serum from a healthy volunteer was also collected as described above, and anti-H. 
pylori IgG levels in the serum from this healthy volunteer were below detection limit; this serum preparation was 
used as the control.
www.nature.com/scientificreports/
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Cell cultures. WT-A10 cells, inductively expressing haemagglutinin (HA)-tagged wild-type CagA, were 
maintained as described previously8. WT-A10 cells were cultured in RPMI1640 medium supplemented with 10% 
heat-inactivated foetal bovine serum (FBS; depleted of exosomes), 10 mM HEPES, 1 mM sodium pyruvate, 0.1 mM 
nonessential amino acids, 2 mM l-glutamine, penicillin G sodium, streptomycin sulphate (1 × ), 500 μ g/mL 
G418, 100 μ g/mL hygromycin B, and 1 μ g/mL doxycycline (Dox) at 37 °C in an atmosphere containing 5% CO2. 
Exosome-depleted FBS was prepared by ultracentrifugation at 120,000 × g for 5 h at 4 °C using a 50.2 Ti rotor 
(Beckman Coulter). AGS cells were cultured in RPMI1640 medium supplemented with 10% heat-inactivated 
FBS, 10 mM HEPES, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, penicillin G sodium, streptomy-
cin sulphate (1×), 2.2 g/L sodium bicarbonate solution, and 50 μ M 2-mercaptoethanol.
Isolation of exosomes from cell culture supernatants. CagA expression was controlled by the pres-
ence or absence of Dox. WT-A10 cells expressing CagA were cultured without Dox for 96 h. Exosomes derived 
from WT-A10 cells were isolated by differential centrifugation60. Briefly, supernatants were centrifuged at 300 × g 
for 10 min, 2,000 × g for 10 min, and 10,000 × g for 30 min to remove dead cells and cell debris. After filtration 
through a 0.22-μ m filter (Stericup, Millipore Corp., Bedford, MA, USA), the resulting supernatants were centri-
fuged at 120,000 × g for 100 min. Exosome pellets were washed with phosphate-buffered saline (PBS) and resus-
pended in a small volume of PBS for further analysis. Protein concentrations were determined using a Micro BCA 
assay kit (Pierce, Rockford, IL, USA). Exosomes derived from AGS cells, which did not express CagA, were also 
isolated by the same procedure.
Nanoparticle tracking analysis (NTA). The size distribution of exosomes was determined using a 
NanoSight LM10 (NanoSight, Amesbury, UK) with a blue laser. The exosome solution was diluted to about 108–
109 particles/mL for analysis.
Western blotting.  CagA protein and exosome markers (CD9 and HSP70) were detected by western 
blotting. Equal amounts of cell lysates and exosomes were separated by 7.5% or 12.5% SDS-PAGE and trans-
ferred to polyvinylidene difluoride membranes (ATTO Co., Ltd., Japan). After blocking with 0.5% skim milk 
or Blocking One-P (Nacalai Tesque Inc., Kyoto, Japan) in TBST (20 mM Tris, 500 mM NaCl, pH 7.4, 0.05% 
Tween 20), membranes were blotted with the following primary antibodies: anti-HA antibodies (3F10; Roche), 
anti-CagA antibodies (AUSTRAL Biologicals), anti-phosphotyrosine antibodies (ab10321 [PY20]; Abcam), 
anti-CD9 antibodies (ab92726; Abcam), and anti-HSP70 antibodies (ab5439; Abcam). The membranes were 
then incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies and ECL Western Blotting 
Detection Reagents (GE Healthcare). The bands were visualised using LAS-4000 (GE-Healthcare). For detection 
of tyrosine-phosphorylated CagA, the blot was first probed with anti-phosphotyrosine antibodies, stripped with 
EzReprobe reagent (ATTO Co., Ltd., Japan), and then reprobed with anti-CagA antibodies.
Transmission electron microscopy (TEM). Exosomes were placed on 100-mesh formvar-coated copper 
grids pretreated with 1% Alcian blue for 5 min. After rinsing with distilled water, exosomes in 2% paraformal-
dehyde (PFA) were absorbed onto grids for 10 min. Samples were stained with 2.5% phosphotungstic acid and 
examined using an HT7700-TEM (Hitachi, Japan) at an accelerating voltage of 100 kV.
CagA localisation on exosomes. To determine CagA localisation on exosomes, exosomes were incubated 
with trypsin (16.6 μ g/1 μ g exosomes) in the absence or presence of 0.2% TritonX-100 at 37 °C for 5 min. The sam-
ples were then immediately mixed with SDS sample buffer, heated at 95 °C for 5 min, and analysed by SDS-PAGE 
and western blotting.
Uptake of PKH67-labeled exosomes into AGS cells.  Exosomes were labelled with a PKH67 Green 
Fluorescent Cell Linker Kit for General Cell Membrane Labelling (Sigma-Aldrich, St. Louis, MO, USA) accord-
ing to the manufacturer’s protocol. Briefly, exosome solution in 1 mL of Diluent C was mixed with PKH67 dye 
solution in Diluent C and then incubated for 5 min. The reaction was stopped by adding an equal volume of 
1% BSA. PKH67-labelled exosomes were isolated by ultracentrifugation and resuspended in PBS. To investigate 
the localisation of exosomes in AGS cells, PKH67-labelled CagA-positive exosomes or CagA-negative exosomes 
(5 μ g/well) were incubated with AGS cells for 24 h. The cells were washed three times with PBS and then fixed 
in 4% paraformaldehyde. Cells were washed three times with PBS, mounted with ProLong antifade reagent 
(Invitrogen), and observed using a confocal laser scanning microscope LSM780 (Carl Zeiss, Germany).
Changes in the morphology of AGS cells after exposure to CagA-expressing exosomes.  AGS 
cells (2.1 × 104 cells/well) were seeded into CELLview glass-bottomed dishes (Greiner BIO-ONE, Frickenhausen, 
Germany) for 24 h. Five micrograms of CagA-positive or CagA-negative exosomes were added to the cells and 
incubated for 24 h. Changes in AGS cell morphology (i.e., the hummingbird phenotype) were examined by 
microscopy. The hummingbird phenotype was defined as cells in which the ratio of the longest to shortest diam-
eters was greater than 2.5-fold. Two hundred cells from each sample were counted for each of three independent 
experiments and analysed using NIH Image J (NIH, Bethesda, MD, USA).
Isolation of exosomes from serum. Isolation of exosomes from serum was carried out using a method 
similar to that described above. Briefly, serum was diluted with PBS before centrifugation at 300, 2000, and 
10,000 × g. The supernatant was further ultracentrifuged at 120,000 × g. Exosome pellets were washed with PBS 
and resuspended in a small volume of PBS for further analysis. The sizes and morphologies of serum-derived 
exosomes were analysed by NTA and TEM, respectively.
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LC-MS/MS analysis of serum-derived exosomes. Exosomal proteins were lysed in Laemmli sample 
buffer and reduced with 10 mM Tris (2-carboxyethyl) phosphine (Sigma-Aldrich) for 30 min at 37 °C, followed 
by alkylation with 50 mM iodoacetamide (Sigma-Aldrich) for 45 min in the dark at 25 °C. Proteins were separated 
on SDS-PAGE and stained with CBB. After desalting and drying excised gel bands, proteins were digested with 
Trypsin GOLD (Promega, Madison, WI, USA) at 37 °C for 16 h. The resulting peptides were extracted and ana-
lysed using an LTQ-Orbitrap-Velos mass spectrometer (Thermo Fisher Scientific) combined with an UltiMate 
3000 RSLC nano-flow HPLC system (DIONEX Corporation). Protein identification analysis was performed 
using a SEQUEST database search with Proteome Discoverer 1.4 software (Thermo Fischer Scientific). The tan-
dem mass spectrometry (MS/MS) spectra were searched against the Homo sapiens + Helicobacter pylori protein 
database in SwissProt. A false discovery rate of 1% and peptide rank of 1 were set for peptide identification filters. 
Extracted ion chromatograms were depicted with mass tolerance at 1 ppm.
Statistical analysis. Statistical tests were performed with two-tailed Student’s t-tests. Differences with 
P-values of less than 0.001 were considered statistically significant.
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